Aidigong Maternal & Child Health Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Aidigong Maternal & Child Health han disminuido a una tasa media anual de -25.4%, mientras que en la industria Healthcare los beneficios crecieron en un 4.8% anualmente. Los ingresos han ido creciendo a una tasa media de 6.7% al año.

Información clave

-25.4%

Tasa de crecimiento de los beneficios

-23.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare	11.3%
Tasa de crecimiento de los ingresos	6.7%
Rentabilidad financiera	-23.4%
Margen neto	-32.0%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Take Care Before Jumping Onto Aidigong Maternal & Child Health Limited (HKG:286) Even Though It's 28% Cheaper

Mar 22

A Look At The Fair Value Of Aidigong Maternal & Child Health Limited (HKG:286)

Jul 06

Aidigong Maternal & Child Health Limited (HKG:286) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough

Jun 14

Calculating The Intrinsic Value Of Aidigong Maternal & Child Health Limited (HKG:286)

Mar 27

Is Aidigong Maternal & Child Health Limited (HKG:286) Trading At A 24% Discount?

Dec 21

Is Aidigong Maternal & Child Health (HKG:286) Using Debt In A Risky Way?

Oct 13

Estimating The Fair Value Of Aidigong Maternal & Child Health Limited (HKG:286)

Sep 02

Aidigong Maternal & Child Health (HKG:286) Has A Somewhat Strained Balance Sheet

Jun 29

Aidigong Maternal & Child Health (HKG:286) Use Of Debt Could Be Considered Risky

Aug 31

Do Institutions Own Aidigong Maternal & Child Health Limited (HKG:286) Shares?

Feb 21

Is Aidigong Maternal & Child Health Limited's (HKG:286) Stock Price Struggling As A Result Of Its Mixed Financials?

Jan 17

Aidigong Maternal & Child Health's(HKG:286) Share Price Is Down 14% Over The Past Three Years.

Dec 12

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Aidigong Maternal & Child Health. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

SEHK:286 Ingresos, gastos y beneficios (HKD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Dec 23	555	-177	257
30 Sep 23	606	-152	257
30 Jun 23	658	-127	257
31 Mar 23	669	-146	263
31 Dec 22	680	-165	269
30 Sep 22	664	-123	225
30 Jun 22	647	-80	181
31 Mar 22	645	-37	176
31 Dec 21	643	5	171
30 Sep 21	622	-189	178
30 Jun 21	601	-384	186
31 Mar 21	601	-383	178
31 Dec 20	601	-381	171
30 Sep 20	653	-172	169
30 Jun 20	704	37	167
31 Mar 20	657	24	145
31 Dec 19	611	11	123
30 Sep 19	492	3	92
30 Jun 19	374	-5	60
31 Mar 19	376	-1	63
31 Dec 18	377	2	65
30 Sep 18	452	2	64
30 Jun 18	528	3	64
31 Mar 18	501	2	54
31 Dec 17	475	1	45
30 Sep 17	496	8	43
30 Jun 17	517	14	41
31 Mar 17	536	28	45
31 Dec 16	555	42	49
30 Sep 16	583	51	45
30 Jun 16	610	59	41
31 Mar 16	570	47	37
31 Dec 15	530	34	32
30 Jun 15	485	27	38
31 Mar 15	422	24	35
31 Dec 14	360	20	33
30 Jun 14	17	-10	18
31 Mar 14	13	-6	15
31 Dec 13	9	-3	12
30 Sep 13	9	1	28
30 Jun 13	8	-8	44

Ingresos de calidad: 286 actualmente no es rentable.

Margen de beneficios creciente: 286 actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 286 no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 25.4% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de 286 en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: 286 no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Healthcare (13.4%).

Rentabilidad financiera

Alta ROE: 286 tiene una rentabilidad financiera negativa (-23.39%), ya que actualmente no es rentable.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Aidigong Maternal & Child Health Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings: EPS and revenues miss analyst expectations

Aidigong Maternal & Child Health Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: HK$0.005 loss per share (vs HK$0.014 loss in 1H 2022)

First half 2023 earnings released: HK$0.005 loss per share (vs HK$0.014 loss in 1H 2022)

Aidigong Maternal & Child Health Limited to Report First Half, 2023 Results on Aug 31, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Recent updates

Full year 2023 earnings: EPS and revenues miss analyst expectations

Take Care Before Jumping Onto Aidigong Maternal & Child Health Limited (HKG:286) Even Though It's 28% Cheaper

Aidigong Maternal & Child Health Limited has filed a Follow-on Equity Offering in the amount of HKD 62.09021 million.

Aidigong Maternal & Child Health Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

New minor risk - Insider selling

Chairman & CEO recently sold HK$8.4m worth of stock

New major risk - Share price stability

Chairman & CEO recently bought HK$1.4m worth of stock

New minor risk - Shareholder dilution

Chairman of the Board & CEO recently bought HK$247k worth of stock

Aidigong Maternal & Child Health Limited Announces Board and Committee Changes

Aidigong Maternal & Child Health Limited Announces Resignation of Guo Qifei Has as Non-Executive Director

First half 2023 earnings released: HK$0.005 loss per share (vs HK$0.014 loss in 1H 2022)

First half 2023 earnings released: HK$0.005 loss per share (vs HK$0.014 loss in 1H 2022)

Aidigong Maternal & Child Health Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023

Aidigong Maternal & Child Health Limited to Report First Half, 2023 Results on Aug 31, 2023

Executive Director recently bought HK$6.3m worth of stock

A Look At The Fair Value Of Aidigong Maternal & Child Health Limited (HKG:286)

Aidigong Maternal & Child Health Limited (HKG:286) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough

Full year 2022 earnings: EPS and revenues miss analyst expectations

Calculating The Intrinsic Value Of Aidigong Maternal & Child Health Limited (HKG:286)

Now 22% undervalued after recent price drop

Aidigong Maternal & Child Health Limited Announces Director Appointments

Is Aidigong Maternal & Child Health Limited (HKG:286) Trading At A 24% Discount?

Aidigong Maternal & Child Health Limited announced that it expects to receive HKD 224.719102 million in funding from Zhuhai Deyou Bohui Enterprise Management Consulting (Limited Partnership)

Now 24% undervalued after recent price drop

Aidigong Maternal & Child Health Limited Announces Executive Changes

Price target decreased to HK$0.60

Less than half of directors are independent

Is Aidigong Maternal & Child Health (HKG:286) Using Debt In A Risky Way?

First half 2022 earnings released: HK$0.014 loss per share (vs HK$0.006 profit in 1H 2021)

Now 25% undervalued

Estimating The Fair Value Of Aidigong Maternal & Child Health Limited (HKG:286)

First half 2022 earnings released: HK$0.014 loss per share (vs HK$0.006 profit in 1H 2021)

Aidigong Maternal & Child Health Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Aidigong Maternal & Child Health Limited Announces Resignation of Wong Kin Man as a Non-Executive Director

Aidigong Maternal & Child Health (HKG:286) Has A Somewhat Strained Balance Sheet

Aidigong Maternal & Child Health Limited, Annual General Meeting, Jun 28, 2022

Aidigong Maternal & Child Health Limited Announces Resignation of Yang Zhibo as Non-Executive Director

Price target decreased to HK$0.65

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Chairman of the Board & CEO recently bought HK$1.2m worth of stock

First half 2021 earnings released: EPS HK$0.006 (vs HK$0.007 in 1H 2020)

Independent Non Executive Director Yang Guang Mai has left the company

Aidigong Maternal & Child Health (HKG:286) Use Of Debt Could Be Considered Risky

First half 2021 earnings released: EPS HK$0.006 (vs HK$0.007 in 1H 2020)

Aidigong Maternal & Child Health Limited has completed a Follow-on Equity Offering in the amount of HKD 117.8 million.

An unknown buyer entered into an agreement to acquire 49% stake Shenzhen Wanqi Marine Bio Tech Company Limited from Aidigong Maternal & Child Health Limited (SEHK:286) for HKD 25 million.

Full year 2020 earnings released: HK$0.10 loss per share (vs HK$0.004 profit in FY 2019)

Aidigong Maternal & Child Health Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Do Institutions Own Aidigong Maternal & Child Health Limited (HKG:286) Shares?

New 90-day high: HK$0.62

Is Aidigong Maternal & Child Health Limited's (HKG:286) Stock Price Struggling As A Result Of Its Mixed Financials?

New 90-day low: HK$0.45

Aidigong Maternal & Child Health's(HKG:286) Share Price Is Down 14% Over The Past Three Years.

New 90-day low: HK$0.50

New 90-day low: HK$0.52

New 90-day low: HK$0.56

Aidigong Maternal & Child Health Limited to Report First Half, 2020 Results on Aug 28, 2020

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta